摘要
目的:探讨细胞周期相关蛋白p53和p16基因在非小细胞肺癌(NSCLC)中的表达及其与临床病理因素的关系。方法:采用免疫组化SP法检测80例NSCLC组织中p53和p16的表达和组织学类型、分期等临床病理参数之间的关系。结果:在80例NSCLC组织中,p53、p16的表达率分别为55%(44/80)、41.25%(33/80)。其中,66例患者显示至少有一种基因表达异常。除p16蛋白的表达与肿瘤组织学类型之间有相关性,p53、p16蛋白的表达异常与其他临床病理参数均无相关性。结论:p53和p16蛋白异常表达是NSCLC中的常见事件。NSCLC的发生与p53/p21和pRb/p16两条重要的细胞生长周期调控路径密切相关。
Objective: To investigate the cell cycle related proteins p53 and p16 in non -small cell lung cancer (NSCLC) and evaluate their correlation with clinicopathological factors. Methods : Total of 80 cases of NSCLC specimens were studied for expression of p53 and p16 by immunohistochemical technique SP method. Results: Forty - four(55% ) and thirty - three (41, 25% ) of 80 patients revealed aberrant immunostaining p53 and p16 respectively. While 66 cases showed that at least one gene with abnormal protein expression. There was no correlation of p53 or p16 expression with the clinicopathologic features except the loss of p16 expression was significantly greater in squamous cell carcinoma than in adenocarcinoma cases. Conclusion : The results suggest that abnormal expression of cell cycle related proteins p53 and p16 is common in lung cancer and the disruption of p53/p21and pRb/pl6 pathways plays an significant role in NSCLC tumorigenesis. Further studies are needed to confirm the role of p53 and p16 in the biologic behavior of the tumor,
出处
《现代肿瘤医学》
CAS
2007年第5期629-632,共4页
Journal of Modern Oncology
基金
安徽省教育厅自然科学研究项目(编号:2002kj220)